What does the cancer drug list multiplier (5x, 16x, 20x) mean in a Singapore shield plan?

Cancer Drug List Multiplier in Integrated Shield Plans (IPs)

The cancer drug list multiplier (5x, 16x, or 20x) relates to the subsidy limits for cancer drug treatments under MediShield Life and Integrated Shield Plans (IPs). This multiplier determines the level of subsidy you receive based on whether the drug is on the Standard Drug List (SDL), the Drug List Plus (DLP), or if you opt for treatment outside these lists.

MediShield Life Subsidy Structure:

• Standard Drug List (SDL): Drugs on this list receive the highest subsidy rates, typically 75% or 50% depending on the treatment type and setting.
• Drug List Plus (DLP): Drugs on this list receive a lower subsidy rate, typically 50% or 30%.

IP Multipliers and Medisave Usage:

When you have an Integrated Shield Plan (IP), the multiplier dictates how much of your treatment cost is covered by MediSave, subject to annual limits. The knowledge provided indicates that Medisave can be used for cancer drugs up to specific limits:

• $600 per month for drugs on the SDL or DLP.
• $1,200 per month if the drug is not on either list, or if you opt for treatment outside the standard subsidy framework.

While the specific 5x, 16x, or 20x multipliers are typically used by insurers to define the coverage tiers within their IP plans (often relating to the claimable amount relative to the MediShield Life payout structure), the key takeaway for a CPF user is the Medisave usage limit. For cancer treatment, you can use your Medisave up to $600/month (or $1,200/month if opting out of the standard subsidy structure) for approved treatments, regardless of the IP multiplier, provided you meet the criteria set by the Ministry of Health (MOH) and CPF Board. Any costs exceeding these limits, or the portion not covered by MediShield Life/IP, must be paid in cash or from other means.

Note: The exact definition of the 5x, 16x, 20x multipliers is determined by MOH/IP providers based on the cost-effectiveness tiers of the drugs, which directly impacts the subsidy level.